Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

July 31, 2027

Conditions
Ischemic Stroke
Interventions
DRUG

Intravenous thrombolysis + edaravone

The patient underwent intravenous t-PA thrombolysis and sublingual administration of edaravone tablets in the prehospital ambulance. Intravenous t-PA thrombolysis was performed in accordance with international guidelines: t-PA dose was calculated according to 0.9mg/kg; 10% of the total dose was injected intravenously, and the remaining 90% was administered intravenously at a uniform rate within one hour.

DRUG

IV thrombolysis + placebo (control group)

Patients underwent intravenous t-PA thrombolysis + placebo sublingual administration. The method of intravenous t-PA thrombolysis is in accordance with the international guideline standards: t-PA dose is calculated according to 0.9mg/kg; 10% of the total dose is injected intravenously, and the remaining 90% is administered intravenously at a constant rate within 1 hour.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tiantan Hospital of Capital Medical University, Beijing

All Listed Sponsors
collaborator

Xing'an League People's Hospital

UNKNOWN

collaborator

Suzhou First People's Hospital

UNKNOWN

collaborator

Nanyang nanshi Hospital

UNKNOWN

collaborator

Nanjing Baixinyu Pharmaceutical Co., Ltd.

UNKNOWN

lead

Ruijun Ji

OTHER